welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Upcoming events – pivotal data loom for Novavax and Mallinckrodt
Welcome to your weekly digest of approaching regulatory and clinical readouts. Novavax is up 4% today thanks to topline results from a phase II trial showing that its Nanoflu influenza vaccine caused “vigorous immune responses” to four strains of flu, and that these responses were enhanced when the group’s Matrix-M adjuvant was added to the vaccine.
But an even more meaningful event is approaching. Novavax’s lead asset, a vaccine against respiratory syncytial virus, is in phase III, and after its disastrous failure two years ago in a study that was intended to be pivotal this is its last chance.
Resvax, also known as RSV F Vaccine since it targets the fusion protein of the virus, crashed out of the Resolve trial, testing it in prevention of moderate to severe RSV-associated lower respiratory tract disease, in mid-2016.
expertly curated content related to this topic
-
Familial Polyposis and Lynch Syndrome Review March 2014http://www.slideshare.net/douglasriegert...
-
Surveillance of FAP: A Prospective Blinded Comparison of Capsule Endoscopy and Other GI Imaging to Detect Small Bowe...BACKGROUND : Familial adenomatous polypo...
-
Ignacio Blanco, MD, PhDIgnacio Blanco practices as a cancer gen...
-
Rectal Cancers in Patients with Familial Adenomatous PolyposisPatients with familial adenomatous polyp...
-
Anal Transitional Zone Neoplasia in Patients with Familial Adenomatous Polyposis After Restorative Proctocolectomy a...BACKGROUND : Restorative proctocolectomy...
-
Evaluating Causes of Death in Familial Adenomatous PolyposisBACKGROUND : Familial adenomatous polypo...
-
Familial Adenomatous Polyposis (FAP)http://canprevent.com/wp-content/uploads...